论文部分内容阅读
据报道,胺碘酮用药后所引发的严重心动过缓并不常见。此外,有关胺碘酮治疗心律失常引发心动过缓相关研究亦少见。本文拟就房颤(AF)老人接受胺碘酮是否将增加需植入起搏器治疗的心动过缓风险进行了分析。对象与方法 8770例心肌梗死后老人,年龄≥65岁。均伴有新发AF,且多数接受了胺碘酮治疗,其中477例为用药后引发了严重心动过缓并已植入了起搏器治疗者;另有1908例为用药后未引发心动过缓者。尔后经多元逻辑回归分析使用
It is reported that amiodarone caused serious bradycardia after treatment is not common. In addition, the relevant research on amiodarone in treatment of arrhythmia caused by bradycardia is also rare. This article aims to analyze whether amiodarone in elderly patients with AF will increase the risk of bradycardia when implanted with a pacemaker. Subjects and methods 8770 elderly after myocardial infarction, age ≥ 65 years. Were associated with new onset of AF, and the majority of patients received amiodarone treatment, 477 of which caused serious bradycardia after treatment and have been implanted pacemaker treatment; another 1908 cases did not lead to cardiac after treatment Slower. After multiple logistic regression analysis